Patents by Inventor Serge H. Boyer
Serge H. Boyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10709718Abstract: This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: GrantFiled: July 2, 2018Date of Patent: July 14, 2020Assignee: Metabasis Therapeutics, Inc.Inventors: K. Raja Reddy, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Publication number: 20180303856Abstract: This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: ApplicationFiled: July 2, 2018Publication date: October 25, 2018Inventors: K. Raja Reddy, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Patent number: 10034891Abstract: The invention pertains to the use of compounds represented by the formula, Q-G1-G2-G3-G4-Z, where Q is The compounds can be used as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: GrantFiled: May 11, 2016Date of Patent: July 31, 2018Assignee: Metabasis Therapeutics, Inc.Inventors: K. Raja Reddy, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Publication number: 20160263132Abstract: The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: ApplicationFiled: May 11, 2016Publication date: September 15, 2016Inventors: K. RAJA REDDY, JEFF STEBBINS, SERGE H. BOYER, MARK D. ERION, SCOTT J. HECKER, NICHOLAS BRIAN RAFFAELE, BRETT C. BOOKSER, VENKAT REDDY MALI
-
Patent number: 9340566Abstract: The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: GrantFiled: February 23, 2015Date of Patent: May 17, 2016Assignee: METABASIS THERAPEUTICS, INC.Inventors: K. Raja Reddy, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Publication number: 20150166590Abstract: The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: ApplicationFiled: February 23, 2015Publication date: June 18, 2015Inventors: K. RAJA REDDY, JEFF STEBBINS, SERGE H. BOYER, MARK D. ERION, SCOTT J. HECKER, NICHOLAS BRIAN RAFFAELE, BRETT C. BOOKSER, VENKAT REDDY MALI
-
Patent number: 8962618Abstract: The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohdroxy pridines or primidines as diacylglycerol O-acyltransferase 1 DGAT-1 inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: GrantFiled: April 27, 2012Date of Patent: February 24, 2015Assignee: Metabasis Therapeutics, Inc.Inventors: K. Raja Reddy, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Patent number: 8664195Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: GrantFiled: December 19, 2011Date of Patent: March 4, 2014Assignee: Metabasis Therapeutics, Inc.Inventors: Mark D. Erion, K. Raja Reddy, Serge H. Boyer
-
Publication number: 20120270842Abstract: The invention pertains to use of DGAT-1 inhibitors to treat and/or prevent overweight, obesity and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease. Compounds and compositions suitable for use in the disclosed methods are also provided.Type: ApplicationFiled: April 27, 2012Publication date: October 25, 2012Applicant: Metabasis Therapeutics, Inc.Inventors: K. RAJA REDDY, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Publication number: 20120093729Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: ApplicationFiled: December 19, 2011Publication date: April 19, 2012Applicant: METABASIS THERAPEUTICS, INC.Inventors: Mark D. ERION, K. Raja REDDY, Serge H. BOYER
-
Publication number: 20120046364Abstract: The present invention relates to sulfonic acid containing compounds of formula IB, in which G, R1, R3 and T are as defined in the claims, that bind to thyroid receptors in the liver. Activation of these receptors results in modulation of gene expression of genes regulated by thyroid hormones. The compounds can be used to treat diseases and disorders including metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome X and diabetes.Type: ApplicationFiled: February 9, 2010Publication date: February 23, 2012Applicant: METABASIS THERAPEUTICS, INC.Inventors: Serge H. Boyer, Scott J. Hecker, Mali Venkat Reddy
-
Patent number: 8080536Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: GrantFiled: September 24, 2010Date of Patent: December 20, 2011Assignee: Metabasis Therapeutics, Inc.Inventors: Mark D. Erion, K. Raja Reddy, Serge H. Boyer
-
Publication number: 20110009356Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: ApplicationFiled: September 24, 2010Publication date: January 13, 2011Applicant: Metabasis Therapeutics, Inc.Inventors: Mark D. ERION, K. Raja Reddy, Serge H. Boyer
-
Patent number: 7829552Abstract: The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.Type: GrantFiled: November 19, 2004Date of Patent: November 9, 2010Assignee: Metabasis Therapeutics, Inc.Inventors: Mark D. Erion, Hongjian Jiang, Serge H. Boyer
-
Patent number: 7816345Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: GrantFiled: July 18, 2007Date of Patent: October 19, 2010Assignee: Metabasis Therapeutics, Inc.Inventors: Mark D. Erion, K. Raja Reddy, Serge H. Boyer
-
Publication number: 20100081634Abstract: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.Type: ApplicationFiled: May 26, 2006Publication date: April 1, 2010Applicant: METABASIS THERAPEUTICS, INC.Inventors: Mark D. Erion, Hongjian Jiang, Serge H. Boyer
-
Publication number: 20090118236Abstract: The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.Type: ApplicationFiled: November 19, 2004Publication date: May 7, 2009Inventors: Mark D. Erion, Hongjian Jiang, Serge H. Boyer
-
Patent number: 7514419Abstract: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.Type: GrantFiled: May 26, 2005Date of Patent: April 7, 2009Assignee: Metabasis Therapeutics, Inc.Inventors: Mark D. Erion, Hongjian Jiang, Serge H. Boyer
-
Publication number: 20090028925Abstract: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.Type: ApplicationFiled: May 26, 2006Publication date: January 29, 2009Inventors: Mark D. Erion, Hongjian Jiang, Serge H. Boyer
-
Publication number: 20080125605Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: ApplicationFiled: July 18, 2007Publication date: May 29, 2008Inventors: Mark D. Erion, K. Raja Reddy, Serge H. Boyer